Chiara Gabellini

Prof. Dr. Chiara Gabellini

University of Pisa, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
CGChiara Gabellini
Chiara Gabellini
Daniela TrisciuoglioDaniela Trisciuoglio
Daniela Trisciuoglio
MDMarianna Desideri
Marianna Desideri
ACAntonio Candiloro
Antonio Candiloro
YRYlenia Ragazzoni
Ylenia Ragazzoni
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo

1 October 2019 in Neuron
Verified
Journal Article
Closed access
ASAlessandro Sessa
Alessandro Sessa
LFLuca Fagnocchi
Luca Fagnocchi
GMGiuseppina Mastrototaro
Giuseppina Mastrototaro
LMLuca Massimino
Luca Massimino
MZMattia Zaghi
Mattia Zaghi
VBVania Broccoli
Vania Broccoli

13 December 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Daniela TrisciuoglioDaniela Trisciuoglio
Daniela Trisciuoglio
MTMaria Grazia Tupone
Maria Grazia Tupone
MDMarianna Desideri
Marianna Desideri
MMMarta Di Martile
Marta Di Martile
CGChiara Gabellini
Chiara Gabellini
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo
By using human melanoma and glioblastoma cell lines and their derivative BCL-XL overexpressing clones, we investigated the role of BCL-XL in aggressive features of these two tumor histotypes. We found that in both models, BCL-XL overexpression increased in vitro cell migration and invasion and facilitated tumor cells to form de novo vasculogenic structures. Furthermore, BCL-XL overexpressing cells exhibited higher tumors sphere formation capacity and expressed higher levels of some stem cell markers, supporting the concept that BCL-XL plays essential roles in the maintenance of cancer stem cell phenotype. BCL-XL expression reduction by siRNA, the exposure to a BCL-XL-specific inhibitor and the use of a panel of human melanoma cell lines corroborated the evidence that BCL-XL regulates tumor progression-associated properties. Finally, the vascular markers and the vasculogenic mimicry were up-regulated in the BCL-XL overexpressing xenografts derived from both tumor histotypes. In conclusion, our work brings further support to the understanding of the malignant actions of BCL-XL and, in particular, to the concept that BCL-XL promotes stemness and contributes to the aggressiveness of both melanoma and glioblastoma.

1 July 2010 in Neoplasia
Verified
Journal Article
Open access
Alessio PaoneAlessio Paone
Alessio Paone
RGRoberta Galli
Roberta Galli
CGChiara Gabellini
Chiara Gabellini
DLDmitriy Lukashev
Dmitriy Lukashev
DSDonatella Starace
Donatella Starace
ARanna riccioli
anna riccioli
Toll-like receptors (TLRs) recognize microbial/viral-derived components that trigger innate immune response and conflicting data implicate TLR agonists in cancer, either as protumor or antitumor agents. We previously demonstrated that TLR3 activation mediated by its agonist poly(I:C) induces antitumor signaling, leading to apoptosis of prostate cancer cells LNCaP and PC3 with much more efficiency in the former than in the second more aggressive line. The transcription factor hypoxia-inducible factor 1 (HIF-1) regulates several cellular processes, including apoptosis, in response to hypoxia and to other stimuli also in normoxic conditions. Here we describe a novel protumor machinery triggered by TLR3 activation in PC3 cells consisting of increased expression of the specific I.3 isoform of HIF-1 alpha and nuclear accumulation of HIF-1 complex in normoxia, resulting in reduced apoptosis and in secretion of functional vascular endothelial growth factor (VEGF). Moreover, we report that, in the less aggressive LNCaP cells, TLR3 activation fails to induce nuclear accumulation of HIF-1 alpha. However, the transfection of I.3 isoform of hif-1 alpha in LNCaP cells allows poly(I:C)-induced HIF-1 activation, resulting in apoptosis protection and VEGF secretion. Altogether, our findings demonstrate that differences in the basal level of HIF-1 alpha expression in different prostate cancer cell lines underlie their differential response to TLR3 activation, suggesting a correlation between different stages of malignancy, hypoxic gene expression, and beneficial responsiveness to TLR agonists.

27 July 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Daniela TrisciuoglioDaniela Trisciuoglio
Daniela Trisciuoglio
CGChiara Gabellini
Chiara Gabellini
MDMarianna Desideri
Marianna Desideri
EZElio Ziparo
Elio Ziparo
GZGabriella Zupi
Gabriella Zupi
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo
Hypoxia-Inducible Factor 1 (HIF-1) is a transcription factor that is a critical mediator of the cellular response to hypoxia. Enhanced levels of HIF-1α, the oxygen-regulated subunit of HIF-1, is often associated with increased tumour angiogenesis, metastasis, therapeutic resistance and poor prognosis. It is in this context that we previously demonstrated that under hypoxia, bcl-2 protein promotes HIF-1/Vascular Endothelial Growth Factor (VEGF)-mediated tumour angiogenesis. By using human melanoma cell lines and their stable or transient derivative bcl-2 overexpressing cells, the current study identified HIF-1α protein stabilization as a key regulator for the induction of HIF-1 by bcl-2 under hypoxia. We also demonstrated that bcl-2-induced accumulation of HIF-1α protein during hypoxia was not due to an increased gene transcription or protein synthesis. In fact, it was related to a modulation of HIF-1α protein expression at a post-translational level, indeed its degradation rate was faster in the control lines than in bcl-2 transfectants. The bcl-2-induced HIF-1α stabilization in response to low oxygen tension conditions was achieved through the impairment of ubiquitin-dependent HIF-1α degradation involving the molecular chaperone HSP90, but it was not dependent on the prolyl hydroxylation of HIF-1α protein. We also showed that bcl-2, HIF-1α and HSP90 proteins form a tri-complex that may contribute to enhancing the stability of the HIF-1α protein in bcl-2 overexpressing clones under hypoxic conditions. Finally, by using genetic and pharmacological approaches we proved that HSP90 is involved in bcl-2-dependent stabilization of HIF-1α protein during hypoxia, and in particular the isoform HSP90β is the main player in this phenomenon. We identified the stabilization of HIF-1α protein as a mechanism through which bcl-2 induces the activation of HIF-1 in hypoxic tumour cells involving the β isoform of molecular chaperone HSP90.

5 January 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SVSergio Valente
Sergio Valente
PMPaolo Mellini
Paolo Mellini
FSFrancesco Spallotta
Francesco Spallotta
Vincenzo CarafaVincenzo Carafa
Vincenzo Carafa
ANAngela Nebbioso
Angela Nebbioso
AMAntonello Mai
Antonello Mai